Detailed Narrative
GBS Program Update and Regulatory Path
Annexon provided an update on its GBS program with tanruprubart, highlighting it as the first positive placebo-controlled pivotal data in 110 years. The drug is under regulatory review in Europe, and the company plans to submit the U.S. BLA in Q4 FY26. Initial results from the FORWARD study's first cohort of 10 patients showed rapid, clinically meaningful improvement in loss of strength within 4 days, with 4 bed-bound patients regaining ability to walk. The data also showed outsized improvements in severely affected patients, including one weaned from mechanical ventilation within 4 days. These findings are consistent with Phase III results where 90% of patients responded by week 1, supporting a broad treatment label.
GA Program Expansion and Rationale
The ARCHER II Phase III trial for vonaprument in geographic atrophy (GA) was strategically expanded to include an independent Month 24 dual primary endpoint alongside the existing Month 15 primary endpoint. This decision was driven by strong trial execution, including over-enrollment by 30 patients, a patient discontinuation rate below 10%, and dosing compliance over 95%. Management stated the expansion strengthens the program, builds a 'moat' around the franchise, and provides additional time to demonstrate the growing treatment effect observed in proof-of-concept data, without weakening confidence in the Month 15 readout.
Vision Preservation vs. Lesion Growth in GA
Management emphasized that the primary goal for vonaprument in GA is vision preservation, not solely lesion growth reduction. They noted that while lesion growth is a current focus in the community, it has not correlated with vision preservation in previously approved therapies. Annexon's focus is on protecting photoreceptor cells and neuronal units, as measured by ellipsoid zone, which they believe is a more critical biomarker for neurodegenerative disease. They anticipate seeing protection of RPE lesion at later time points based on Phase II data, but prioritize vision outcomes.
Financial Strengthening and Capital Structure
Annexon strengthened its financial position by securing a credit facility with Oxford Finance, providing access to up to $200 million in non-dilutive capital. This facility extends the company's cash runway into 2028, enhancing financial and operational flexibility as it prepares for global commercialization of its programs. The move also diversifies the capital structure and supports both near- and longer-term growth strategies.
Regulatory Designations and Support for Vonaprument
Vonaprument has received Fast Track designation from the FDA and PRIME designation from the EMA, making it the only geographic atrophy program with this status from the EMA. It has also been selected for the EMA's product development coordinator pilot, which offers enhanced regulatory support, including expedited scientific advice and MAA submission readiness. These designations facilitate more frequent engagement with regulators, supporting the program's path towards potential registration.